StockData
SOPHiA GENETICS SA logo

SOPHiA GENETICS SA (SOPH) stock

SOPHNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 3, 2026Score 4/30
$7.44−0.77 (-9.38%)

Close on Nov 16, 2026Market cap $509.54MP/E –Yield –

SOPHiA GENETICS SA grew revenue 18.6% to $77.27M over fiscal 2025. Free cash flow was -$36.47M. At the latest close the market valued the company at $509.54M.

Revenue
$77.27M
+18.6% vs. a year earlier
Operating income
-$70.91M
FY2025
Free cash flow
-$36.47M
FY2025
EPS, diluted
-$1.17
FY2025

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026

Valuation

Market cap
$509.54M
P/E ratio
–
Price to sales
6.59
Price to book
–
Dividend yield
–
Free cash flow yield
-7.16%

Fundamentals

Revenue
$77.27M
Net income
-$79.00M
EPS, diluted
-$1.17
Free cash flow
-$36.47M
Diluted shares
74M

Trading

Previous close
$8.21
Open
$8.07
Day's range
$7.40 – $8.13
Volume
782,480
Average volume (20 days)
669,399
52-week range
$3.83 – $8.98
RSI (14 days)
49.5
Volatility (1 year)
62.7%
Relative volume
1.34×

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodSOPHS&P 500DifferenceSOPH per yearS&P 500 per year
1 month+10.5%-3.1%+13.6 pts
3 months-0.8%-4.5%+3.7 pts
Year to date+59.3%+9.4%+50.0 pts
1 year+72.6%+11.3%+61.3 pts
3 years+103.3%+70.4%+32.9 pts+26.7%+19.4%
5 years-52.0%+68.6%−120.6 pts-13.7%+11.0%

Eight years at a glance

Fiscal years 2018 to 2025, USD

Revenue

$77.27M+18.6% YoY

Gross profit

$52.08M+18.5% YoY

Operating income

-$70.91M

Net income

-$79.00M

EPS, diluted

-$1.17

Free cash flow

-$36.47M
Reported period

Press releases

Releases SOPHiA GENETICS filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About SOPHiA GENETICS

Services-Computer Processing & Data Preparation

SOPHiA GENETICS is a healthcare software company that develops a cloud-based analytics platform for data-driven medicine. Its core product, SOPHiA DDM, standardizes and analyzes complex genomic and multimodal health data for applications across oncology, rare diseases, cardiology, and neurology. The company also offers the Alamut interpretation software, the SOPHiA CarePath multimodal module, and biopharma solutions for clinical trials and companion diagnostics. Its customers include academic and community hospitals, reference and specialty laboratories, and biopharmaceutical firms.

Company profile, executives and history

SOPHiA GENETICS stock: common questions

What is SOPHiA GENETICS's stock price?

SOPH closed at $7.44 on Nov 16, 2026, down 9.38% on the day. Over the past 52 weeks it traded between $3.83 and $8.98.

What is SOPHiA GENETICS's market cap?

SOPHiA GENETICS was worth $509.54M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is SOPH's P/E ratio?

SOPHiA GENETICS lost money over fiscal 2025 (diluted EPS -$1.17), so it has no meaningful P/E ratio.

How much revenue does SOPHiA GENETICS make?

SOPHiA GENETICS reported revenue of $77.27M for fiscal 2025, up 18.6% from a year earlier.

Does SOPHiA GENETICS pay a dividend?

No. SOPHiA GENETICS has not paid a cash dividend over the last twelve months.

How has SOPH stock performed over the past year?

Including dividends, SOPH returned +72.6% over the past year, against +11.3% for the S&P 500.

How many SOPH shares are sold short?

1M shares were sold short at the latest FINRA report, 1.88% of the float, or 2.6 days of average trading volume.

Who are SOPHiA GENETICS's competitors?

Companies most similar to SOPHiA GENETICS by business, industry and size include VERI, INOD, CTW, INFQ, BIRD.

See a number that looks wrong?